S treptococcus pneumoniae remains a leading cause of serious illness and death among young children worldwide. Only a limited number of the 92 known pneumococcal serotypes are responsible for the majority of pneumococcal invasive infections.
1 Although invasive pneumococcal disease (IPD) rates have declined following PCV7 use, nonvaccine serotypes have rapidly increased. [2] [3] [4] Data from the Active Bacterial Core Surveillance indicate that the overall incidence of IPD among children aged <5 years decreased from approximately 99 cases during 1998 to 1999 to 21 cases in 2008 per 100 000 population in both time periods.
5 Because of the need to monitor changes in serotype distribution after widespread use of PCV7, PCV10 and now PCV13, we are reporting one case which to our knowledge is the first reported invasive pneumococal disease with serotype 25.
CASE
Our patient was an 8-month-old female infant who had completed 3 doses of PCV-13 vaccine and who was admitted to the intensive care unit with a 2-day history of fever, lethargy, poor feeding and drowsiness. During the initial examination, she looked drowsy with a Glasgow coma scale of 13/15, and was having arching movements. Her heart rate was 130 beats/minute. Her anterior fontanel was flat and the tone was reduced in all four limbs. Otherwise, the systemic examination was unremarkable.
Emerging invasive nonvaccine pneumoccocal serotype 25
Badria Rashid Al Waili, Suleiman Alola, Esam Albanyan Streptococcus pneumoniae (pneumococcus) is a bacterial pathogen that causes invasive infections, including septicemia and meningitis, as well as noninvasive infections such as community-acquired pneumonia, sinusitis and acute otitis media. Vaccination with pneumococcal conjugate vaccine (PCV7) has significantly reduced the burden of pneumococcal disease; however it targets only seven of the more than 92 pneumococcal serotypes. Concerns have been raised that nonvaccine serotypes could increase in prevalence and reduce the benefits of vaccination. We report one case with invasive nonvaccine serotype 25 that presented with meningitis.
Cerebrospinal fluid (CSF) examination showed a red blood cell of 2161×10 . A CT scan of the head was normal apart from the incidental finding of frontal hygroma. The infant was started on ceftriaxone, vancomycin and acyclovir. The CSF culture reported S pneumoniae sensitive to penicillin, ceftriaxone and cefotaxime. The blood culture was negative. The infant was continued on ceftriaxone for 2 weeks. The CSF culture repeated after 10 days was negative. The infant developed isolated left-sided ophthalmoplegia with divergent squint, but no other neurological squealae. The S pneumoniae serotype was confirmed as serotype 25. There are no reported cases or published data about serotype 25 except for experimental studies. This could be because some laboratories lack the diagnostic tools to determine the serotype, so it is reported as nontypable, or it is possible that it is an emerging nonvaccine serotype. In conclusion, we need ongoing surveillance to monitor the serotypes causing invasive pneumococcal disease to make future plans for prevention.
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